Role of Haematopoietic Stem Cell Transplantation in Peripheral T-Cell Lymphoma
Peripheral T-cell lymphomas (PTCLs) are distinct pathological entities with clinical advancements lagging behind their B-cell lymphoma counterpart. Frequently aggressive in their clinical behaviour, clinicians are constantly challenged with low complete remission rates, early relapses and failure to...
Gespeichert in:
Veröffentlicht in: | Cancers 2020-11, Vol.12 (11), p.3125 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 11 |
container_start_page | 3125 |
container_title | Cancers |
container_volume | 12 |
creator | Abeyakoon, Chathuri van der Weyden, Carrie Harrop, Sean Khot, Amit Dickinson, Michael Yannakou, Costas K. Prince, H. Miles |
description | Peripheral T-cell lymphomas (PTCLs) are distinct pathological entities with clinical advancements lagging behind their B-cell lymphoma counterpart. Frequently aggressive in their clinical behaviour, clinicians are constantly challenged with low complete remission rates, early relapses and failure to achieve long-term responses despite aggressive first-line chemotherapy, resulting in poor overall survival in the majority of patients. There is currently no consensus regarding the optimal therapy for PTCL and treatment approaches are mainly derived from prospective phase II studies, registry data and retrospective studies. Despite its biological heterogeneity, a less than satisfactory “one-size-fits-all” approach has been adopted to date. Although its role remains controversial, for many years, haematopoietic stem cell transplantation has been adopted by clinicians with the aim of overcoming poor outcomes by consolidating responses. In this review, we aim to define the role of both autologous and allogeneic stem cell transplantation in PTCL in both frontline and salvage settings, especially in the context of recent advancements in this field. |
doi_str_mv | 10.3390/cancers12113125 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7692733</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A645023504</galeid><sourcerecordid>A645023504</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-b3a527955265470d94ebd19a05309463211ce351ac72519c47d922242668bd163</originalsourceid><addsrcrecordid>eNpdkc1LAzEQxYMoKtWz1wUvXtbmO81FkKJWKCp-nEOaTtvIbrImW6H_vdGKqHOZB-_HYx6D0AnB54xpPHQ2OEiZUEIYoWIHHVKsaC2l5ru_9AE6zvkVl2GMKKn20UERhEssD9HdY2ygiotqYqG1feyih9676qmHthpD01TPyYbcNTb0tvcxVD5UD5B8t4Jki1t_QdNN261ia4_Q3sI2GY6_9wC9XF89jyf19P7mdnw5rR3To76eMSuo0kJQKbjCc81hNifaYsGw5pKVRg6YINYpKoh2XM01pZRTKUcFlGyALra53XrWwtxB6Ms1pku-tWljovXmrxP8yizju1FSU8VYCTj7DkjxbQ25N63PrlSxAeI6G8qFGDGBFSno6RZd2gaMD4tYEt0nbi4lF5gWjBdquKVcijknWPwcQ7D5fJf59y72Acz-hd4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2455835071</pqid></control><display><type>article</type><title>Role of Haematopoietic Stem Cell Transplantation in Peripheral T-Cell Lymphoma</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><source>EZB Electronic Journals Library</source><creator>Abeyakoon, Chathuri ; van der Weyden, Carrie ; Harrop, Sean ; Khot, Amit ; Dickinson, Michael ; Yannakou, Costas K. ; Prince, H. Miles</creator><creatorcontrib>Abeyakoon, Chathuri ; van der Weyden, Carrie ; Harrop, Sean ; Khot, Amit ; Dickinson, Michael ; Yannakou, Costas K. ; Prince, H. Miles</creatorcontrib><description>Peripheral T-cell lymphomas (PTCLs) are distinct pathological entities with clinical advancements lagging behind their B-cell lymphoma counterpart. Frequently aggressive in their clinical behaviour, clinicians are constantly challenged with low complete remission rates, early relapses and failure to achieve long-term responses despite aggressive first-line chemotherapy, resulting in poor overall survival in the majority of patients. There is currently no consensus regarding the optimal therapy for PTCL and treatment approaches are mainly derived from prospective phase II studies, registry data and retrospective studies. Despite its biological heterogeneity, a less than satisfactory “one-size-fits-all” approach has been adopted to date. Although its role remains controversial, for many years, haematopoietic stem cell transplantation has been adopted by clinicians with the aim of overcoming poor outcomes by consolidating responses. In this review, we aim to define the role of both autologous and allogeneic stem cell transplantation in PTCL in both frontline and salvage settings, especially in the context of recent advancements in this field.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers12113125</identifier><identifier>PMID: 33114606</identifier><language>eng</language><publisher>MDPI AG</publisher><subject>Care and treatment ; Hematopoietic stem cells ; Patient outcomes ; Review ; T cell lymphoma ; Transplantation</subject><ispartof>Cancers, 2020-11, Vol.12 (11), p.3125</ispartof><rights>COPYRIGHT 2020 MDPI AG</rights><rights>2020 by the authors. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c398t-b3a527955265470d94ebd19a05309463211ce351ac72519c47d922242668bd163</citedby><cites>FETCH-LOGICAL-c398t-b3a527955265470d94ebd19a05309463211ce351ac72519c47d922242668bd163</cites><orcidid>0000-0002-8848-9423 ; 0000-0002-0058-2448</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692733/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692733/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53770,53772</link.rule.ids></links><search><creatorcontrib>Abeyakoon, Chathuri</creatorcontrib><creatorcontrib>van der Weyden, Carrie</creatorcontrib><creatorcontrib>Harrop, Sean</creatorcontrib><creatorcontrib>Khot, Amit</creatorcontrib><creatorcontrib>Dickinson, Michael</creatorcontrib><creatorcontrib>Yannakou, Costas K.</creatorcontrib><creatorcontrib>Prince, H. Miles</creatorcontrib><title>Role of Haematopoietic Stem Cell Transplantation in Peripheral T-Cell Lymphoma</title><title>Cancers</title><description>Peripheral T-cell lymphomas (PTCLs) are distinct pathological entities with clinical advancements lagging behind their B-cell lymphoma counterpart. Frequently aggressive in their clinical behaviour, clinicians are constantly challenged with low complete remission rates, early relapses and failure to achieve long-term responses despite aggressive first-line chemotherapy, resulting in poor overall survival in the majority of patients. There is currently no consensus regarding the optimal therapy for PTCL and treatment approaches are mainly derived from prospective phase II studies, registry data and retrospective studies. Despite its biological heterogeneity, a less than satisfactory “one-size-fits-all” approach has been adopted to date. Although its role remains controversial, for many years, haematopoietic stem cell transplantation has been adopted by clinicians with the aim of overcoming poor outcomes by consolidating responses. In this review, we aim to define the role of both autologous and allogeneic stem cell transplantation in PTCL in both frontline and salvage settings, especially in the context of recent advancements in this field.</description><subject>Care and treatment</subject><subject>Hematopoietic stem cells</subject><subject>Patient outcomes</subject><subject>Review</subject><subject>T cell lymphoma</subject><subject>Transplantation</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpdkc1LAzEQxYMoKtWz1wUvXtbmO81FkKJWKCp-nEOaTtvIbrImW6H_vdGKqHOZB-_HYx6D0AnB54xpPHQ2OEiZUEIYoWIHHVKsaC2l5ru_9AE6zvkVl2GMKKn20UERhEssD9HdY2ygiotqYqG1feyih9676qmHthpD01TPyYbcNTb0tvcxVD5UD5B8t4Jki1t_QdNN261ia4_Q3sI2GY6_9wC9XF89jyf19P7mdnw5rR3To76eMSuo0kJQKbjCc81hNifaYsGw5pKVRg6YINYpKoh2XM01pZRTKUcFlGyALra53XrWwtxB6Ms1pku-tWljovXmrxP8yizju1FSU8VYCTj7DkjxbQ25N63PrlSxAeI6G8qFGDGBFSno6RZd2gaMD4tYEt0nbi4lF5gWjBdquKVcijknWPwcQ7D5fJf59y72Acz-hd4</recordid><startdate>20201101</startdate><enddate>20201101</enddate><creator>Abeyakoon, Chathuri</creator><creator>van der Weyden, Carrie</creator><creator>Harrop, Sean</creator><creator>Khot, Amit</creator><creator>Dickinson, Michael</creator><creator>Yannakou, Costas K.</creator><creator>Prince, H. Miles</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8848-9423</orcidid><orcidid>https://orcid.org/0000-0002-0058-2448</orcidid></search><sort><creationdate>20201101</creationdate><title>Role of Haematopoietic Stem Cell Transplantation in Peripheral T-Cell Lymphoma</title><author>Abeyakoon, Chathuri ; van der Weyden, Carrie ; Harrop, Sean ; Khot, Amit ; Dickinson, Michael ; Yannakou, Costas K. ; Prince, H. Miles</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-b3a527955265470d94ebd19a05309463211ce351ac72519c47d922242668bd163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Care and treatment</topic><topic>Hematopoietic stem cells</topic><topic>Patient outcomes</topic><topic>Review</topic><topic>T cell lymphoma</topic><topic>Transplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abeyakoon, Chathuri</creatorcontrib><creatorcontrib>van der Weyden, Carrie</creatorcontrib><creatorcontrib>Harrop, Sean</creatorcontrib><creatorcontrib>Khot, Amit</creatorcontrib><creatorcontrib>Dickinson, Michael</creatorcontrib><creatorcontrib>Yannakou, Costas K.</creatorcontrib><creatorcontrib>Prince, H. Miles</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abeyakoon, Chathuri</au><au>van der Weyden, Carrie</au><au>Harrop, Sean</au><au>Khot, Amit</au><au>Dickinson, Michael</au><au>Yannakou, Costas K.</au><au>Prince, H. Miles</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of Haematopoietic Stem Cell Transplantation in Peripheral T-Cell Lymphoma</atitle><jtitle>Cancers</jtitle><date>2020-11-01</date><risdate>2020</risdate><volume>12</volume><issue>11</issue><spage>3125</spage><pages>3125-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Peripheral T-cell lymphomas (PTCLs) are distinct pathological entities with clinical advancements lagging behind their B-cell lymphoma counterpart. Frequently aggressive in their clinical behaviour, clinicians are constantly challenged with low complete remission rates, early relapses and failure to achieve long-term responses despite aggressive first-line chemotherapy, resulting in poor overall survival in the majority of patients. There is currently no consensus regarding the optimal therapy for PTCL and treatment approaches are mainly derived from prospective phase II studies, registry data and retrospective studies. Despite its biological heterogeneity, a less than satisfactory “one-size-fits-all” approach has been adopted to date. Although its role remains controversial, for many years, haematopoietic stem cell transplantation has been adopted by clinicians with the aim of overcoming poor outcomes by consolidating responses. In this review, we aim to define the role of both autologous and allogeneic stem cell transplantation in PTCL in both frontline and salvage settings, especially in the context of recent advancements in this field.</abstract><pub>MDPI AG</pub><pmid>33114606</pmid><doi>10.3390/cancers12113125</doi><orcidid>https://orcid.org/0000-0002-8848-9423</orcidid><orcidid>https://orcid.org/0000-0002-0058-2448</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2072-6694 |
ispartof | Cancers, 2020-11, Vol.12 (11), p.3125 |
issn | 2072-6694 2072-6694 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7692733 |
source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central; EZB Electronic Journals Library |
subjects | Care and treatment Hematopoietic stem cells Patient outcomes Review T cell lymphoma Transplantation |
title | Role of Haematopoietic Stem Cell Transplantation in Peripheral T-Cell Lymphoma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T20%3A07%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20Haematopoietic%20Stem%20Cell%20Transplantation%20in%20Peripheral%20T-Cell%20Lymphoma&rft.jtitle=Cancers&rft.au=Abeyakoon,%20Chathuri&rft.date=2020-11-01&rft.volume=12&rft.issue=11&rft.spage=3125&rft.pages=3125-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers12113125&rft_dat=%3Cgale_pubme%3EA645023504%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2455835071&rft_id=info:pmid/33114606&rft_galeid=A645023504&rfr_iscdi=true |